Ultragenyx Pharmaceutical | RARE - Current Assets


Ultragenyx Pharmaceutical reported $657M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Agios Pharmaceuticals USD 834.84M 107.21M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
BioCryst Pharmaceuticals USD 373.62M 30.72M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Esperion Therapeutics USD 459.46M 3.11M Mar/2026
Immunic USD 188.76M 165.89M Mar/2026
Insmed USD 1.61B 181.04M Mar/2026
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
Kyowa Hakko Kirin JPY 459.88B 33.47B Mar/2026
MacroGenics USD 182.52M 37.42M Mar/2026
Moderna USD 5.77B 774M Mar/2026
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
PTC Therapeutics USD 2.25B 19.94M Mar/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026
Xoma USD 110.71M 5.78M Sep/2025